1,1-Diazido-2-[2-(2-ethoxyethoxy)ethoxy]ethane

• 分子结构分类: 有机化合物 - 有机盐 - 有机叠氮化物
• 英文名称: 1,1-Diazido-2-[2-(2-ethoxyethoxy)ethoxy]ethane
• 英文别名: 1,1-diazido-2-[2-(2-ethoxyethoxy)ethoxy]ethane
• 化学式: C8H16N6O3
• 分子量: 244.25
• InChiKey: RCVORCJMTXBQGT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  56.4
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• [EN] INHIBITOR IMAGING AGENTS<br/>[FR] AGENTS INHIBITEURS D'IMAGERIE
  申请人：AMERSHAM PLC

  公开号：WO2005049005A1

  公开（公告）日：2005-06-02

  The present invention discloses that imaging agents which comprise a specific type of matrix metalloproteinase inhibitors (MMPi's) of the sulphonamide hydroxamate class labelled with an imaging moiety, are useful diagnostic imaging agents for in vivo imaging and diagnosis of the mammalian body.

  本发明揭示了一种成像试剂，其中包括一种特定类型的矩阵金属蛋白酶抑制剂（MMPi's），属于磺胺基羟肟类，并标记有成像基团，可用于哺乳动物体内成像和诊断的诊断成像试剂。
• [EN] OPTICAL IMAGING CONTRAST AGENTS FOR IMAGING LUNG CANCER<br/>[FR] AGENTS DE CONTRASTE D'IMAGERIE OPTIQUE POUR L'IMAGERIE DU CANCER DU POUMON
  申请人：AMERSHAM HEALTH AS

  公开号：WO2005058370A1

  公开（公告）日：2005-06-30

  The invention provides contrast agents for optical imaging of lung cancer in patients. The contrast agents may be used in diagnosis of lung cancer, for follow up of progress in disease development, for follow up of treatment of lung cancer and for surgical guidance. Further, the invention provides methods for optical imaging of lung cancer in patients.

  该发明提供了用于患者肺癌光学成像的对比剂。这些对比剂可用于肺癌的诊断，用于随访疾病发展进展，用于随访肺癌治疗以及用于手术引导。此外，该发明还提供了患者肺癌光学成像的方法。
• [EN] OPTICAL IMAGING CONTRAST AGENTS FOR IMAGING LUNG CANCER<br/>[FR] AGENTS DE CONTRASTE POUR L'IMAGERIE OPTIQUE
  申请人：AMERSHAM HEALTH AS

  公开号：WO2005058372A1

  公开（公告）日：2005-06-30

  The invention provides contrast agents for optical imaging of prostate cancer in patients. The contrast agents may be used in diagnosis of prostate cancer, for follow up of progress in disease development, for follow up of treatment of prostate cancer and for surgical guidance. Further, the invention provides methods for optical imaging of prostate cancer in patients.

  该发明提供了用于在患者中光学成像前列腺癌的对比剂。这些对比剂可用于前列腺癌的诊断，用于随访疾病发展进展情况，用于随访前列腺癌治疗以及用于手术指导。此外，该发明提供了在患者中进行前列腺癌光学成像的方法。
• [EN] OPTICAL IMAGING CONTRAST AGENTS<br/>[FR] AGENTS DE CONTRASTE POUR IMAGERIE OPTIQUE
  申请人：AMERSHAM HEALTH AS

  公开号：WO2005058371A1

  公开（公告）日：2005-06-30

  The invention provides contrast agents for optical imaging of oesophageal cancer and Barrett's oesophagus in patients. The contrast agents may be used in diagnosis of oesophageal cancer and Barrett's oesophagus, for follow up of progress in disease development, for follow up of treatment of oesophageal cancer and Barrett's oesophagus and for surgical guidance. Further, the invention provides methods for optical imaging of oesophageal cancer and Barrett's oesophagus in patients.

  该发明提供了用于患者食管癌和巴雷特食管的光学成像对比剂。这些对比剂可用于诊断食管癌和巴雷特食管，用于随访疾病进展情况，用于随访食管癌和巴雷特食管的治疗以及用于手术指导。此外，该发明提供了在患者中光学成像食管癌和巴雷特食管的方法。
• Imaging Agents with Improved Pharmacokinetic Profiles
  申请人：Cuthbertson Alan

  公开号：US20080095704A1

  公开（公告）日：2008-04-24

  The invention relates to compounds suitable for use in an imaging agent said imaging agent showing an improved pharmacokinetic profile.

  该发明涉及适用于成像剂的化合物，所述成像剂显示出改进的药代动力学特性。